Cilazapril

Cilazapril is used for high blood pressure and congestive heart failure although neither is a USFDA approved indication for this drug. Cilazapril is a long-acting angiotensin-converting enzyme (ACE) inhibitor. The pharmacologic effects of ACE inhibition result in a decrease in systemic vascular resistance, reducing blood pressure, preload, and afterload. Reductions in blood pressure are not accompanied by changes in heart rate, pressor sensitivity to exogenous norepinephrine, or baroreceptor sensitivity.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Cilazapril

CAS Registry Number:
92077-78-6
Brand names:
Inhibace®, Dynorm®, Inhibestril®, Vascace®, Zapril®, Zobox®
Cost:
$679 USD

CHECK AVAILABILITY

The OEL monograph for this compound is under development. Let us know if you'd like to be notified when this document becomes available.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

  • The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
  • A listing of all cited references utilized in the derivation of the OEL and ADE
  • An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

  • Fully documented. Over 20 pages in length, with calculations and cited references.
  • Save time! Unsurpassed delivery with instant download.
  • Save money. Similar documents cost 5-12 times as much.
  • Stay current. Automatic notification of revisions.

Inquiries on monograph availability

The OEL/ADE monograph for Cilazapril is under development.

You can contact us and let us know if you'd like to be notified when this document becomes available.

HBEL

If you're wondering about HBEL, we have something for you.

Search OEL Fastrac

Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.

Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.
  • K. Rosenthal
  • Director of Manufacturing